IntegraDose Compounding Services Faces Second Fentanyl Citrate Recall for Subpotency, Raising Supply Chain Risk
IntegraDose Compounding Services LLC has initiated a nationwide Class II recall for 376 cassettes of subpotent fentaNYL Citrate, Sterile CADD for Injection. This marks the company's second recall for Fentanyl Citrate and its third for subpotency, signaling systemic quality control issues. Procurement and supply chain leaders must immediately assess inventory and diversify sourcing to mitigate significant patient safety and supply disruption risks.
FDA Class II Recall: IntegraDose's Subpotent Fentanyl Citrate Injection
IntegraDose Compounding Services LLC, based in Shoreview, Minnesota, has initiated a voluntary, firm-initiated Class II recall for 376 cassettes of fentaNYL Citrate, Sterile CADD for Injection, 2,2500 mcg/50mL in Sterile Water. This critical action, designated recall number D-0548-2026, commenced on May 12, 2026, following the discovery that the product was subpotent. The affected lot, identified as 20260310FEN-1, carries an expiration date of September 6, 2026. The product, bearing NDC 71139-6030-1, was distributed nationwide, indicating a broad exposure across the United States healthcare system. For procurement directors, this means an immediate and urgent need to identify and quarantine all affected inventory. Subpotent fentaNYL Citrate poses a significant patient safety risk, as it may lead to inadequate pain management, potentially causing prolonged suffering, increased healthcare interventions, and adverse clinical outcomes. Regulatory affairs heads must ensure rapid compliance with FDA recall procedures, including accurate reporting and communication with downstream users. The nationwide distribution pattern amplifies the logistical challenges and the potential for widespread clinical impact, demanding a swift and coordinated response from all entities involved in the supply chain.
Operational Impact: IntegraDose's Shoreview Compounding Facility
The recall originates from IntegraDose Compounding Services LLC's facility at 3650 Victoria St N Ste 900, Shoreview, MN 55126-2906. As a compounding pharmacy, IntegraDose plays a crucial role in providing customized sterile preparations, often filling gaps in the market for specific dosages or formulations not readily available from large pharmaceutical manufacturers. The fentaNYL Citrate, Sterile CADD for Injection, is a vital opioid analgesic used for pain management, particularly in hospital settings. A subpotent product from such a facility directly undermines patient care and trust in compounded medications. For supply chain VPs, this event highlights the inherent risks associated with relying on single-source compounding facilities, especially for critical care medications. The specific nature of compounded drugs often means fewer alternative suppliers are readily available, making disruptions from a key provider like IntegraDose particularly impactful. Business development executives should note the potential for market shifts as healthcare providers seek more robust and reliable sourcing strategies for sterile compounded injectables. The incident underscores the necessity for rigorous quality control within compounding operations to ensure product efficacy and patient safety.
Supply Chain Vulnerability: Nationwide Exposure to Subpotent Opioid Analgesics
The nationwide distribution of IntegraDose's subpotent fentaNYL Citrate cassettes creates substantial supply chain vulnerability for healthcare providers across the United States. Hospitals, clinics, and other medical facilities that rely on this specific compounded formulation for pain management and anesthesia will face immediate challenges. Procurement directors must not only manage the recall logistics but also rapidly identify and qualify alternative sources for fentaNYL Citrate to prevent treatment interruptions. The subpotency issue means patients receiving this drug may not achieve the intended therapeutic effect, leading to uncontrolled pain, potential for adverse events from subsequent interventions, and increased resource utilization within healthcare systems. This directly translates to elevated operational costs and potential reputational damage for healthcare providers. Regulatory affairs heads must ensure their organizations are fully compliant with FDA guidelines for handling recalled products and reporting any adverse events linked to the subpotent drug. The incident underscores the critical need for robust supplier qualification programs that include thorough assessments of quality control systems, particularly for high-risk sterile compounded products like fentaNYL Citrate.
IntegraDose's Recurring Quality Issues: A Pattern of Regulatory Non-Compliance
This recall of subpotent fentaNYL Citrate represents a concerning pattern of quality control deficiencies at IntegraDose Compounding Services LLC. This is not an isolated incident; the company has a documented history of regulatory non-compliance related to product quality. In February 2024, IntegraDose initiated a recall for Vasopressin due to sub-potency, indicating a systemic issue with ensuring accurate drug concentration. Furthermore, in April 2024, the company recalled Fentanyl Citrate — the same molecule involved in the current event — due to sterility failure. While the specific defect differs (sterility versus subpotency), the recurrence of issues with Fentanyl Citrate and the repeated problem of subpotency across different products (Vasopressin, now Fentanyl) points to fundamental weaknesses in IntegraDose's manufacturing and quality assurance processes. For business development executives, this pattern suggests a supplier with elevated risk, potentially impacting long-term partnerships and market share. Procurement teams should view IntegraDose as a high-risk vendor, necessitating a re-evaluation of current contracts and a strategic shift towards diversifying their supplier base to mitigate future disruptions and ensure patient safety. Regulatory affairs must anticipate heightened scrutiny from the FDA on IntegraDose's operations.
Strategic Implications: Navigating Ongoing Regulatory Scrutiny and Supply Risk
The ongoing Class II recall for IntegraDose's subpotent fentaNYL Citrate, coupled with the company's history of quality failures, carries significant strategic implications for the global chemical and life sciences industry. IntegraDose Compounding Services LLC faces intensified regulatory scrutiny from the FDA. While this specific event is a firm-initiated recall, the pattern of subpotency and sterility issues could lead to more severe enforcement actions, including formal Warning Letters, increased inspections, or even injunctions if corrective actions are deemed insufficient. For procurement directors, the imperative is clear: reduce reliance on IntegraDose for critical compounded sterile products. This necessitates a proactive strategy to identify, qualify, and onboard alternative suppliers, a process that can be lengthy and resource-intensive, particularly for specialized compounded formulations. Supply chain VPs must develop robust contingency plans to manage potential future disruptions from IntegraDose or similar compounding pharmacies. Business development executives should monitor the competitive landscape for opportunities arising from IntegraDose's diminished reliability, as other compliant compounding services or pharmaceutical manufacturers may gain market share. This event serves as a stark reminder that comprehensive supplier risk management, focusing on consistent quality and regulatory compliance, is paramount for maintaining patient safety and supply chain resilience.